Notice To Attend the Annual General Meeting of the Shareholders for Vitrolife AB

Stockholm, SWEDEN


STOCKHOLM, Sweden, March 04, 2002 (PRIMEZONE) -- The shareholders of Vitrolife AB (publ) are hereby invited to the Annual General Meeting on 3 April 2002 at 2 p.m., at SEB Goteborg (main entrance, 4th floor), Ostra Hamngatan 24, Gothenburg.

Notice of Attendance

Shareholders who wish to attend the Annual General Meeting must be registered in the shareholders' register kept by VPC AB (the Swedish Securities Register) on Friday, March 22, 2002 and give notice of attendance to the Company no later than on Tuesday, April 2, 2002 at 12 am, by mail to Vitrolife AB, Molndalsvagen 30 A, SE-412 63 Gothenburg, or by fax to +46 (0)31 721 80 99, at which the number of assistants shall be stated.

When giving notice of attendance, please state name, personal identity number (date of birth) or company registration number, address and telephone number. If the shareholder intends to be represented by a representative, complete documents showing the due authorization of the representative such as certificate of registration and power of attorney shall be attached to the notice of attendance.

Shareholders who have registered their shares by a bank, a brokerage firm or another nominee must, in order to be entitled to attend the general meeting, temporarily register its shares in their own name. Such registration must be effectuated on Friday, March 22, 2002, which means that the shareholder in due time before such date must notify its nominee.

Proposed Agenda

1. Election of chairman at the meeting.

2. Preparation and approval of voting list.

3. Approval of the agenda.

4. Election of one or two persons to confirm the minutes

5. Resolution as to whether the meeting has been duly convened.

6. Presentation of the Annual Report and the Auditor's Report as well as the Group Annual Report and the Group Auditor's Report

7. Resolutions as to a) the adoption of the Profit and Loss Statement and the Balance Sheet as well as the Group Profit and Loss Statement and the Group Balance Sheet

b) the allocation of the Company's loss in accordance with the adopted Balance Sheet, c) the discharge from liability for the directors of the board and the managing director.

8. Resolution as to the number of members and deputy members of the Board of Directors.

9. Resolution as to the remuneration to the Board of Directors and the auditors.

10. Election of the members of the Board of Directors.

11. The closing of the meeting.

Dividend

The board recommends that no dividend is paid out for the financial year 2001.

Documents

Accounts and the auditor's report will be kept available to the shareholders at the Company during two weeks before the Annual General Meeting of shareholders and will be sent free of charge by the Company to shareholders on their request. The documents will also be available at the home page of the Company.

Vitrolife

Vitrolife's business mission is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs. Vitrolife intends to further expand the Company's production capacity to meet an expected increase in demand for its products, as well as strengthen its global market position as a leading company in the development of innovative cell and tissue technologies.

Vitrolife believes that the number of procedures performed annually involving tissue and cell technologies will increase as new treatments are introduced and existing treatments are improved. In addition, Vitrolife expects that the regulation surrounding approval processes and quality control for its products will increase. Vitrolife aims to create competitive advantages from this regulation by meeting and exceeding expected future demands of regulatory authorities, ahead of the Company's competitors.

Since it commenced its operations in 1993, Vitrolife has expanded rapidly. The Company currently has more than 90 employees and sells its products in over 80 countries. During the latest five-year period, sales have steadily increased by and totaled more than SEK 100 million for the fiscal year 2001.

The Vitrolife share is listed on the Stockholm Exchange (Stockholmsborsen) O-list under the ticker VITR.

This information was brought to you by Waymaker http://www.waymaker.net



            

Contact Data